A case report highlights the use of larotrectinib as an adjuvant therapy in a patient with resected secretory carcinoma-like lung adenocarcinoma harboring the EML4-NTRK3 fusion. This finding contributes to the understanding of targeted therapies for rare lung cancers.
adjuvant larotrectinib in a resected secretory carcinoma like lung adenocarcinoma harboring eml4 ntrk3 fusion case report
Original title: “Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report.”